106 related articles for article (PubMed ID: 31262109)
1. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
Wang SX; Zhang XW; Wang XX; An CM; Zhang YB; Liu W; Zhao YF; He XH; Li ZJ; Niu LJ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun; 54(6):439-444. PubMed ID: 31262109
[No Abstract] [Full Text] [Related]
2. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
3. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
[TBL] [Abstract][Full Text] [Related]
4. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
Kraft IL; Akshintala S; Zhu Y; Lei H; Derse-Anthony C; Dombi E; Steinberg SM; Lodish M; Waguespack SG; Kapustina O; Fox E; Balis FM; Merino MJ; Meltzer PS; Glod JW; Shern JF; Widemann BC
Clin Cancer Res; 2018 Feb; 24(4):753-765. PubMed ID: 29187393
[No Abstract] [Full Text] [Related]
6. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
[TBL] [Abstract][Full Text] [Related]
7. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
8. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Ramos HE; Hecht F; Berdelou A; Borget I; Leboulleux S; Baudin E; Schlumberger M
Endocrine; 2021 Feb; 71(2):434-442. PubMed ID: 32691271
[TBL] [Abstract][Full Text] [Related]
9. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
10. A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
Yin Y; Qiu XY; Zhang YH; Zhang B
Medicine (Baltimore); 2019 Aug; 98(31):e16392. PubMed ID: 31374006
[TBL] [Abstract][Full Text] [Related]
11. YAP confers resistance to vandetanib in medullary thyroid cancer.
Wang H; Tang J; Su Z
Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
[TBL] [Abstract][Full Text] [Related]
12. Rare complications of multikinase inhibitor treatment.
Pitoia F; Schmidt A; Bueno F; Abelleira E; Jerkovich F
Arch Endocrinol Metab; 2018; 62(6):636-640. PubMed ID: 30624504
[TBL] [Abstract][Full Text] [Related]
13. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Valerio L; Bottici V; Matrone A; Piaggi P; Viola D; Cappagli V; Agate L; Molinaro E; Ciampi R; Tacito A; Ramone T; Romei C; Elisei R
Endocr Relat Cancer; 2020 Jan; 27(2):97-110. PubMed ID: 31804969
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Kreissl MC; Bastholt L; Elisei R; Haddad R; Hauch O; Jarząb B; Robinson B; Colzani R; Foster M; Weiss R; Schlumberger M
J Clin Oncol; 2020 Aug; 38(24):2773-2781. PubMed ID: 32584630
[TBL] [Abstract][Full Text] [Related]
17. An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.
García-Moreno RM; Moreno-Domínguez Ó; Castelo-Fernández B; Yébenes-Gregorio L; Torres-Sánchez I; Álvarez-Escolá C
Oncol Res Treat; 2021; 44(10):568-572. PubMed ID: 34515201
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
19. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
[TBL] [Abstract][Full Text] [Related]
20. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]